Eisai Co., Ltd., together with it’s research institute (the?KAN Research Institute, Inc. or KRI) aims to discover and develop new drugs based on novel therapeutic concepts
The company is dedicated to conducting discovery research based on the concept of Integrative Cell Biology for Medicine in its three areas of therapeutic focus – refractory immune diseases, neurodegenerative diseases and cancer relapse and metastasis, and aims to discover and develop biologic therapies such as antibodies. Eisai (KRI) laboratories are prepared with future installation of an antibody-drug conjugate (ADC) production facility and collaborative lab spaces for academic and medical researchers which has strengthened the company’s antibody research capability while further promoting its open innovation initiatives with external partnerships, one of the core strategies of the company.
4-6-10 Koishikawa, Bunkyo-ku,
Tokyo 112-8088, Japan
Web: Eisai Co., Ltd.
